Lecia V. Sequist, MD, MPH
Associate Professor, Department of Medicine, Harvard Medical School
Assistant Physician, Medicine, Massachusetts General Hospital
DF/HCC Program AffiliationLung Cancer
Member, Clinical Science Coordinating Committee
I am a member of the clinical research faculty at the Massachusets General Hospital Cancer Center and Harvard Medical School. I devote 75% of my time to clinical research, specifically developing and implementing clinical trials and translational correlative science studies under the guidance of my clinical mentor, Dr. Thomas Lynch and my scientific mentor, Dr. Daniel Haber. My work brings novel treatments for lung cancer to the clinic and also defines methods of tailoring therapeutic recommendations to individual patients with lung cancer. Currently, I am studying non-small cell lung cancer with somatic EGFR activating mutations, therapeutic agents that interact with the EGF receptor, the novel compound TLK286 in combination with standard chemotherapy for non-small cell lung cancer, the prognostic significance of circulating tumor cells in cancer patients, combination chemotherapy in elderly patients with non-small cell lung cancer, and functional assessment as a predictor of risk during chemotherapy in elderly patients.
View All Publications